Why Investors Didn't Like Inovio's Seemingly Positive Clinical Results

Earlier this month, Inovio Pharmaceuticals (NASDAQ: INO) announced results from a late-stage study of immunotherapy candidate VGX-3100 in treating precancerous cervical dysplasia. Although the primary and secondary endpoints of the study were achieved, investors didn't seem impressed. In this Motley Fool Live video, recorded on March 3, 2021, Fool.com contributors Keith Speights and Brian Orelli talk about why Inovio's results for VGX-3100 weren't very well received.

Continue reading

Source Fool.com